EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 154 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $182,711 | -40.6% | 11,586 | +10.0% | 0.00% | -50.0% |
| Q4 2022 | $307,822 | -64.0% | 10,531 | -67.5% | 0.00% | -71.4% |
| Q3 2022 | $855,000 | -30.8% | 32,377 | +16.5% | 0.01% | -30.0% |
| Q2 2022 | $1,235,000 | -74.2% | 27,793 | -71.3% | 0.01% | -68.8% |
| Q1 2022 | $4,795,000 | -34.0% | 96,890 | -32.1% | 0.03% | -34.7% |
| Q4 2021 | $7,266,000 | -20.1% | 142,692 | -12.5% | 0.05% | -19.7% |
| Q3 2021 | $9,098,000 | +23.7% | 163,099 | -5.1% | 0.06% | +22.0% |
| Q2 2021 | $7,355,000 | +11.5% | 171,840 | +8.8% | 0.05% | -2.0% |
| Q1 2021 | $6,595,000 | -8.7% | 158,005 | +1.9% | 0.05% | -19.0% |
| Q4 2020 | $7,222,000 | +26.8% | 155,070 | +15.7% | 0.06% | +6.8% |
| Q3 2020 | $5,696,000 | +26.8% | 134,076 | +43.2% | 0.06% | +20.4% |
| Q2 2020 | $4,492,000 | +54.4% | 93,630 | +48.1% | 0.05% | +32.4% |
| Q1 2020 | $2,909,000 | +132.2% | 63,241 | +203.2% | 0.04% | +208.3% |
| Q4 2019 | $1,253,000 | +31.6% | 20,860 | +23.9% | 0.01% | 0.0% |
| Q3 2019 | $952,000 | +5.2% | 16,836 | +3.6% | 0.01% | -7.7% |
| Q2 2019 | $905,000 | – | 16,246 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |